Prescriber Scope of Practice for General Psychiatry in Pennsylvania

If you’re a psychiatrist, PMHNP, or prescriber wondering whether you can legally prescribe controlled substances through telehealth — or trying to figure out which states allow it and what the current rules are — you’re not alone. The regulatory landscape for telepsychiatry has been a moving target since 2020, and with new DEA rules on the horizon in 2026, it’s critical to understand where things stand today and what’s coming next.

The short answer: Yes, psychiatrists and qualified prescribers can currently prescribe controlled substances via telehealth without an initial in-person exam, thanks to federal emergency flexibilities extended through December 31, 2026. But state laws add layers of complexity, and the DEA is finalizing permanent rules that will change how this works going forward — especially for providers prescribing stimulants, benzodiazepines, and buprenorphine.

Let’s break down exactly what you need to know: federal DEA requirements, state-by-state telehealth prescribing laws, and how your scope of practice (MD vs PMHNP) affects what you can do on a platform like Klarity Health.

The Current State of Federal Telehealth Prescribing Rules

The Ryan Haight Act and COVID-Era Changes

Normally, federal law (the Ryan Haight Act of 2008) requires at least one in-person medical evaluation before a provider can prescribe controlled substances to a patient via the internet. This was designed to stop rogue online pill mills, but it also created a barrier for legitimate telehealth psychiatry.

When COVID hit in March 2020, the DEA invoked emergency authority to waive the in-person requirement. As of January 2026, HHS and the DEA have extended this flexibility through the end of 2026, allowing psychiatrists and other prescribers to initiate treatment with Schedule II–V controlled medications via telehealth (video consultation) without ever seeing the patient face-to-face.

What this means for your practice right now:

• You can evaluate a new patient via two-way video and prescribe Adderall for ADHD, Klonopin for anxiety, or buprenorphine for opioid use disorder — all without an in-person visit
• The evaluation must meet the standard of care: thorough history, mental status exam, diagnosis, treatment plan — just as you would in-person
• You must be licensed in the state where the patient is located and have a DEA registration for that state
• You should document the encounter thoroughly (many state boards are watching telehealth prescribing closely after some high-profile over-prescribing scandals)

Important caveat: If a patient has already been seen in person by you or another provider, there’s no federal restriction on telehealth prescribing for that patient — the Ryan Haight Act in-person requirement is already satisfied. The extension mainly helps providers treat new patients they’ve never met face-to-face.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Changing: DEA’s Proposed Permanent Telehealth Rules

The current extension is temporary. The DEA is working on three proposed permanent rules announced in January 2025 that will replace the COVID-era waivers. Here’s what psychiatrists need to know:

1. Buprenorphine for Opioid Use Disorder (OUD)

The DEA proposes allowing providers to prescribe buprenorphine via telehealth (including audio-only) for up to 6 months before requiring an in-person visit. This is huge for addiction psychiatry — it means you could start MAT (medication-assisted treatment) with a patient remotely and manage them for half a year before needing face-to-face contact.

After 6 months, the rule would require an in-person evaluation to continue prescribing. This balances access with safety and acknowledges that telehealth has been incredibly effective for OUD treatment.

2. Special Telemedicine Registration for Schedule II Prescribing

This is the big one for general psychiatry. The DEA is creating a ‘Special Telemedicine Prescriber Registration’ that would allow qualified providers to prescribe controlled substances to new patients via telehealth without any in-person exam.

For Schedule III–V substances (like Xanax, Ambien, Suboxone), any DEA-registered provider could apply for this special registration.

For Schedule II substances (like Adderall, Ritalin, Vyvanse for ADHD), the DEA is initially limiting eligibility to specific specialties, and psychiatrists are explicitly included. Board-certified psychiatrists could obtain this registration and legally prescribe stimulants and other Schedule II medications via telehealth indefinitely, with no in-person requirement.

This would be a game-changer: instead of worrying about the temporary extension expiring, psychiatrists with the special registration could build sustainable telepsychiatry practices treating ADHD, narcolepsy, and other conditions requiring Schedule II medications.

The DEA is also proposing that telehealth platforms must register with the DEA and participate in a national PDMP (Prescription Drug Monitoring Program) to prevent prescription shopping and diversion. Expect more administrative requirements, but also clearer legal pathways.

3. VA Continuity of Care Rule

The third proposed rule creates a special provision for the VA system, allowing any VA provider to prescribe controlled substances via telehealth to a patient who had an in-person exam with any VA clinician (even if it was a different provider). This treats the entire VA as one integrated system. While this mainly affects federal providers, it signals the DEA’s thinking on continuity of care and team-based models.

Timeline: These rules are in the public comment phase as of early 2026. The DEA will review comments and finalize the rules sometime in 2026. Until then, the temporary extension remains in effect. Psychiatrists should plan for compliance with the new registration and reporting requirements that are likely coming.

State Telehealth Prescribing Laws: Where It Gets Complicated

Federal law sets the floor, but states can impose stricter rules. Here’s what you need to know for the six largest psychiatric telehealth markets:

California: Telehealth-Friendly with Strict Compliance

California doesn’t require an in-person exam for telehealth prescribing. You can establish a valid physician-patient relationship via video and prescribe controlled substances following the standard of care.

Key requirements:

• CURES PDMP: You must check California’s prescription monitoring database before prescribing any Schedule II–IV controlled substance to a new patient, and every 4 months for ongoing treatment
• E-prescribing: Mandatory for all prescriptions (not just controlled substances) since January 2022
• NP scope: California is transitioning to full practice authority for PMHNPs. By 2026, experienced NPs will be able to practice and prescribe independently without physician oversight — making them valuable for telehealth platforms

Texas: Strict NP Limits, Chronic Pain Restrictions

Texas allows telehealth prescribing of controlled substances under federal law, but has unique restrictions:

Critical limits:

• NPs cannot prescribe Schedule II in outpatient settings — only in hospitals or hospice. This means a Texas PMHNP cannot prescribe Adderall for ADHD; you need a physician for any Schedule II prescriptions
• Chronic pain rule: Texas prohibits prescribing controlled substances for chronic pain via telehealth without an in-person visit (this mainly affects pain management, not psychiatry, but be aware if treating somatic conditions)
• PDMP: Mandatory check of Texas PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol

For telehealth platforms operating in Texas, you need a collaborative model pairing NPs with psychiatrists for Schedule II prescribing.

Florida: Psychiatric Exception to Telehealth Ban

Florida has one of the most detailed telehealth laws, and it includes a ban on prescribing Schedule II controlled substances via telehealth — with a critical exception.

You CAN prescribe Schedule II via telehealth if it’s for:

1. Psychiatric disorder treatment
2. Inpatient hospital care
3. Hospice care
4. Nursing home resident care

Since ADHD is a psychiatric disorder, Florida psychiatrists can prescribe stimulants via telehealth. You cannot, however, prescribe Schedule II opioids for chronic pain via telehealth (not within the exceptions).

Other Florida rules:

• Out-of-state providers can register as Florida telehealth providers without full licensure, but the same prescribing restrictions apply
• E-FORCSE PDMP: Must check before prescribing any controlled substance to patients 16+
• NP restrictions: PMHNPs in Florida require physician collaboration and cannot practice independently

Document your indication clearly: if you’re prescribing Adderall, note it’s for ADHD (psychiatric treatment) to fall within Florida’s exception.

New York: Strong PDMP and E-Prescribing Mandates

New York allows telehealth prescribing with no in-person requirement, but has some of the strictest compliance requirements:

• I-STOP PDMP: Mandatory check every time you prescribe a Schedule II, III, or IV controlled substance (one of the most stringent PDMP laws in the country)
• E-prescribing: Required for all prescriptions (controlled and non-controlled) since 2016
• NP scope: Experienced PMHNPs (>3,600 practice hours) can practice independently and prescribe controlled substances with full authority

New York’s telehealth environment is favorable for psychiatry, but the PDMP and e-prescribing requirements are non-negotiable.

Pennsylvania: No Special Telehealth Law, Standard Rules Apply

Pennsylvania doesn’t have a comprehensive telehealth statute, but telemedicine is permitted under general medical board guidance. You can establish a patient relationship via video and prescribe following standard of care.

Key points:

• PDMP: Mandatory check before prescribing opioids or benzodiazepines (and periodically for ongoing treatment)
• E-prescribing: Required for controlled substances
• NP collaboration: PMHNPs must have collaborative agreements with at least two physicians for prescriptive authority; cannot practice independently

Pennsylvania is relatively straightforward but requires traditional supervision models for NPs.

Illinois: Full NP Practice with Some Controlled Substance Limits

Illinois allows telehealth prescribing and has moved toward NP independence, but with nuances:

• NP Full Practice Authority: PMHNPs with 4,000 hours of experience and additional training can obtain FPA licenses and prescribe independently
• Controlled substance limits: Even with FPA, NPs must have a physician consultation arrangement to prescribe Schedule II opioids or benzodiazepines, with 30-day supply limits
• PDMP: Mandatory check before prescribing opioids; encouraged for other controlled substances
• E-prescribing: Required for all controlled substances as of January 2023

Illinois is telehealth-friendly but the NP consultation requirement for benzos and Schedule II opioids adds a layer of complexity.

Psychiatrist vs PMHNP: Scope of Practice Matters

Psychiatrists (MD/DO) have full independent practice authority in all states. You can prescribe any controlled substance consistent with DEA and state rules. No supervision required, no scope limitations beyond your training and the standard of care.

PMHNPs face state-dependent restrictions:

• Full practice states (NY, CA by 2026, IL with FPA): Can evaluate, diagnose, and prescribe independently, including controlled substances
• Reduced practice states (PA, OH, many others): Require collaborative agreements with physicians but can prescribe with that agreement in place
• Restricted practice states (TX, FL, SC): Require physician supervision and often prohibit prescribing certain controlled substances (especially Schedule II in Texas)

For telehealth platforms, this means:

• In states like New York and California, you can recruit independent PMHNPs who function like psychiatrists
• In Texas and Florida, you need collaborative structures or focus on psychiatrist recruitment
• In states with partial restrictions (like Illinois), experienced NPs can handle most cases but may need physician backup for specific prescriptions

The Economics of Telehealth Prescribing: Why Platforms Like Klarity Make Sense

Let’s talk about the business reality of building a telepsychiatry practice.

DIY Marketing Costs: If you’re trying to acquire patients on your own, the real economics look like this:

• Google Ads: Mental health keywords cost $15–40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200–400+, and that’s after you’ve spent months testing and optimizing campaigns
• SEO: Takes 6–12 months of consistent investment before generating meaningful patient flow. You need expertise, content, backlinks — or you’re hiring an agency for $2,000–5,000/month
• Directory listings: Psychology Today, Zocdoc, and others charge monthly fees ($30–100+) and you compete with hundreds of providers on the same page. Zocdoc also charges $35–100 per booking on top of subscription fees
• Total acquisition cost: When you factor in agency fees, ad spend, staff time qualifying leads, no-show rates from cold leads, failed campaigns, and months before results — acquiring a qualified psychiatric patient through DIY marketing typically costs $200–500+

Most solo providers don’t have the $3,000–5,000/month marketing budget or the patience to wait 6–12 months for SEO to work.

The Klarity Model: Instead of gambling on marketing channels with uncertain ROI, Klarity uses a pay-per-appointment model (similar to Zocdoc’s listing fee approach). You pay a standard fee per new patient lead — only when a qualified patient books with you.

The value proposition:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

Frame it this way: instead of spending $3,000–5,000/month on marketing with no guarantee of results, you pay only when a patient shows up ready to be treated. That’s guaranteed ROI versus gambling on whether your SEO investment will ever pay off.

For providers starting out or scaling up, a platform that handles patient acquisition removes the risk entirely. You can focus on what you do best — treating patients — while the platform handles the marketing, credentialing, tech, and billing infrastructure.

Compliance Checklist for Telepsychiatry Prescribers

Whether you’re joining a platform or building your own practice, here’s what you need to stay compliant:

Federal requirements:

• ✅ DEA registration in each state where patients are located
• ✅ Use two-way audio-video for initial evaluations (audio-only generally only acceptable for buprenorphine OUD treatment or established patients)
• ✅ Document thorough evaluations meeting the standard of care
• ✅ Complete the 8-hour MATE Act training on substance use disorder and pain management (required for all DEA registrations/renewals since June 2023)
• ✅ E-prescribe controlled substances (required by most states and Medicare)
• ✅ Stay updated on DEA’s final telehealth rules expected in 2026

State-specific requirements:

• ✅ Full medical license in each state where patients are located (or valid telehealth registration if available, like Florida’s)
• ✅ Check state PDMP before prescribing controlled substances (frequency varies by state — some require every prescription, others just initial)
• ✅ Follow state telehealth consent requirements (many states require informing patients about telehealth and obtaining consent)
• ✅ If you’re a PMHNP, ensure you meet state scope requirements (collaborative agreement if needed, verify which schedules you can prescribe)
• ✅ Comply with any state-specific prescribing limits (like Florida’s psychiatric exception rule, Texas chronic pain ban, etc.)

Platform/practice requirements:

• ✅ HIPAA-compliant telehealth technology
• ✅ Malpractice insurance covering telehealth and all states you practice in
• ✅ Secure e-prescribing system with two-factor authentication
• ✅ Documentation system for telehealth encounters and PDMP checks
• ✅ Emergency protocols (how to handle crisis situations when patient is remote)

FAQ: Telehealth Prescribing for Psychiatrists

Can I prescribe Adderall via telehealth right now?

Yes, under current federal rules (extended through December 31, 2026), you can prescribe Adderall and other Schedule II stimulants to a new patient via telehealth after conducting an appropriate video evaluation. State law may add requirements (like Florida requiring it to be for psychiatric treatment, which ADHD qualifies as). Once DEA finalizes permanent rules, psychiatrists will likely be able to obtain a special telemedicine registration to continue prescribing Schedule II medications remotely.

Do I need an in-person visit before prescribing controlled substances via telehealth?

Not under current federal rules (through end of 2026). Some states may have stricter requirements, but the six states covered here (CA, TX, FL, NY, PA, IL) generally allow telehealth prescribing consistent with federal law. Always check your state’s specific rules and document your evaluation thoroughly.

Can PMHNPs prescribe controlled substances via telehealth?

It depends on the state. In full practice states (New York, California by 2026), experienced PMHNPs can prescribe independently including controlled substances. In restricted states like Texas, PMHNPs cannot prescribe Schedule II at all in outpatient settings. Florida requires physician collaboration. Check your state’s NP scope of practice laws.

What happens when the DEA extension expires?

The DEA is expected to finalize permanent telehealth rules in 2026. Psychiatrists will likely be able to obtain a ‘special telemedicine registration’ to continue prescribing Schedule II and other controlled substances via telehealth without in-person exams. Buprenorphine prescribing via telehealth will be allowed for 6 months before requiring in-person. Stay tuned for final rules — they’re designed to maintain access while adding oversight.

Do I need to check the PDMP every time I prescribe?

It varies by state. New York requires a PDMP check every time you prescribe Schedule II–IV. California requires it before the first prescription and every 4 months. Texas requires it for opioids and benzos. Pennsylvania requires it before prescribing opioids or benzos. Check your state’s specific PDMP mandate and make it part of your workflow.

Can I practice telepsychiatry across state lines?

Yes, but you must be licensed in each state where your patients are located. Some states offer expedited licensing through the Interstate Medical Licensure Compact (IMLC), which includes California, Texas, Illinois, and Pennsylvania. You’ll also need DEA registrations for each state. Out-of-state telehealth registrations (like Florida’s) can be an option but come with restrictions.

Is audio-only (telephone) telehealth acceptable for prescribing?

Generally no, with exceptions. The DEA’s current allowance for controlled substance prescribing via telehealth assumes interactive audio-video. The proposed buprenorphine rule would specifically allow audio-only for OUD treatment. Some states (like California and New York) permit audio-only telehealth for mental health services, but for prescribing controlled substances to new patients, video is the safer standard. Audio-only might be acceptable for established patients or non-controlled medications depending on state law.

The Bottom Line: Telepsychiatry Prescribing in 2026

Telepsychiatry prescribing is legal, growing, and here to stay — but the rules are evolving. Right now, you have broad flexibility under federal emergency waivers to prescribe controlled substances via telehealth. The DEA’s upcoming permanent rules will likely maintain access while adding structure through special registrations and periodic in-person requirements for certain medications.

For psychiatrists, the future looks promising: you’ll be able to build sustainable telehealth practices with clear legal pathways for prescribing stimulants, benzodiazepines, and other controlled medications. For PMHNPs, scope of practice varies dramatically by state — in some places you’ll have full authority, in others you’ll need physician collaboration.

The key is staying compliant: know your state’s rules, check PDMPs, e-prescribe, document thoroughly, and keep up with regulatory changes.

And when it comes to building your patient base, recognize the real economics: DIY marketing is expensive, time-consuming, and risky. Platforms like Klarity Health that handle patient acquisition, credentialing, and infrastructure let you focus on clinical care while paying only when patients actually show up. That’s a smarter economic model than spending thousands per month on marketing with no guaranteed results.

Ready to practice telepsychiatry with a steady flow of pre-qualified patients and full compliance support? Explore how Klarity Health’s platform handles the patient acquisition, credentialing, and regulatory complexity so you can focus on treating patients. [Learn more about joining Klarity’s provider network →]

Sources

1. HHS Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ – www.hhs.gov, January 2, 2026

2. DEA Press Release: ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Medications’ – www.dea.gov, January 16, 2025

3. Florida Statutes §456.47: ‘Use of telehealth to provide services’ – www.leg.state.fl.us, 2025 edition

4. Akerman LLP: ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth’ – www.akerman.com, March 2023

5. Texas Medical Board: ‘Prescriptive Authority FAQs’ – www.tmb.texas.gov, Updated 2024

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices